AndreaBozzo/ceres-open-data-index huggingface dataset:
Treatment Episode Data Set: Discharges (TEDS-D-2007)

<p>The Treatment Episode Data Set -- Discharges (TEDS-D) is a national census data system of annual discharges from substance abuse treatment facilities. TEDS-D provides annual data on the number and characteristics of persons discharged from public and private substance abuse treatment programs that receive public funding. Data collected both at admission and at discharge is included. The unit of analysis is a treatment discharge. TEDS-D consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.<br />
A sister data system, called the Treatment Episode Data Set -- Admissions (TEDS-A), collects data on admissions to substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.<br />
TEDS-D variables that are required to be reported are called the "Minimum Data Set (MDS)", while those that are optional are called the "Supplemental Data Set (SuDS)".<br />
Variables unique to TEDS-D, and not part of TEDS-A, are the length of stay, reason for leaving treatment, and service setting at time of discharge. TEDS-D also provides many of the same variables that exist in TEDS-A. This includes information on service setting, number of prior treatments, primary source of referral, sex, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008) .<br />
Substances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.<br />
Created variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.This study has 1 Data Set.</p>
Compound 525641: N,N-Dimethyl-N'-octyl-p-methylbenzamidine

Chemical compound data from PubChem database. IUPAC Name: N,N,4-trimethyl-N'-octylbenzenecarboximidamide. Molecular Formula: C18H30N2. Molecular Weight: 274.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Practical Guidance to Developing Comprehensive Child Welfare Information System (CCWIS) Advance Planning Documents

This webinar summarized the different Advance Planning Documents (Planning, Implementation, Annual, As-Needed, and Operational) and then advised how to compose quality Advance Planning Documents.  This webinar included suggestions to save time and simplify the process, and tips on dos and don'ts that affect approval.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525529: (3-Chloro-4-octyloxy-phenyl)-acetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-chloro-4-octoxyphenyl)acetate. Molecular Formula: C17H25ClO3. Molecular Weight: 312.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Archive: COVID-19 LTC Program Vaccinations and Trends in the United States, Jurisdiction

The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS, Walgreens, and Managed Health Care Associates, Inc. The program offered on-site COVID-19 vaccination services for residents of nursing homes and assisted living facilities. The Federal Pharmacy Partnership for LTC Program was in effect after vaccines became available to April 23, 2021. This is the historical archived data related to the LTC Program and represents data that was shown on COVID Data Tracker through September 30, 2021. Twelve variables that provided data on residents and staff vaccinated through the program were removed from the COVID-19 Vaccinations in the United States,Jurisdiction dataset. LTC was removed as an option from the location variable in the following datasets: COVID-19 Vaccinations in the United States,Jurisdiction and COVID-19 Vaccination Trends in the United States,National and Jurisdictional.
Compound 525493: 5-Methyl-3-thia-1-hexanethiol

Chemical compound data from PubChem database. IUPAC Name: 2-(2-methylpropylsulfanyl)ethanethiol. Molecular Formula: C6H14S2. Molecular Weight: 150.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528865: 2,4,5,6-Tetrathianonane, 3-ethyl

Chemical compound data from PubChem database. IUPAC Name: 1-methylsulfanyl-1-(propyltrisulfanyl)propane. Molecular Formula: C7H16S4. Molecular Weight: 228.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400715-T1: [Translated] REMOVABLE PARKING HOUSE

The garage has a skeleton support structure with vertical supports, horizontal roof supports (11) and several track plates (12) forming the drive-on surface on the roof supports. The drive-on track plates are mounted on the roof supports with the interposition of a grooved profiled body (16) which runs in the longitudinal direction of the gap (21) between adjoining plates and underneath same. The roof support preferably has an I-profiled section and the grooved profiled body is mounted with its underneath on the top web of same. The profiled body can be made of elastic plastics.
Forced oscillation assessment of respiratory mechanics in ventilated patients

The forced oscillation technique (FOT) is a method for non-invasively assessing respiratory mechanics that is applicable both in paralysed and non-paralysed patients. As the FOT requires a minimal modification of the conventional ventilation setting and does not interfere with the ventilation protocol, the technique is potentially useful to monitor patient mechanics during invasive and noninvasive ventilation. FOT allows the assessment of the respiratory system linearity by measuring resistance and reactance at different lung volumes or end-expiratory pressures. Moreover, FOT allows the physician to track the changes in patient mechanics along the ventilation cycle. Applying FOT at different frequencies may allow the physician to interpret patient mechanics in terms of models with pathophysiological interest. The current methodological and technical experience make possible the implementation of portable and compact computerised FOT systems specifically addressed to its application in the mechanical ventilation setting.
NNDSS - Table II. Giardiasis to Haemophilus influenza

NNDSS - Table II. Giardiasis to Haemophilus influenza - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.
 
Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.
FY 2008 Children's Bureau Discretionary Grant and Cooperative Agreement Awards

This document provides a list of Children's Bureau discretionary grants and cooperative agreements awarded in fiscal year 2008:

Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect (CFDA # 93.670)
Up to $500,000 per year for 5 years.

Cooperative Agreements for Child Welfare Technical Assistance Implementation Centers (CFDA # 93.652)
Up to $1,410,000 per year for 5 years.

CAPTA: National Quality Improvement Center on Preventing the Abuse and Neglect of Infants and Young Children (CFDA # 93.670)
Up to $1,700,000 per year for 5 years.

CAPTA: National Quality Improvement Center on Differential Response in Child Protective Services (CFDA # 93.670)
Up to $2,000,000 per year for 5 years.

Adoption Opportunities: Diligent Recruitment of Families for Children in the Foster Care System (CFDA # 93.652)
Up to $400,000 per year for 5 years.

Child Welfare Training: National Child Welfare Workforce Initiatives (CFDA # 93.648)
Up to $3,300,000 per year for 5 years.

Child Welfare Training: Curriculum Development and Evaluation for Healthy Marriage and Relationship Education (CFDA # 93.648)
Up to $250,000 per year for 5 years.

Abandoned Infants Assistance: Comprehensive Support Services for Families Affected by Substance Abuse and/or HIV/AIDS (CFDA # 93.551)
Up to $475,000 per year for 4 years.

Grants to Tribes, Tribal Organizations, and Migrant Programs for Community-Based Child Abuse Prevention Programs (CFDA # 93.590)
Up to $138,963 per year for 3 years.

Metadata-only record linking to the original dataset. Open original dataset below.
Family Group Decision-Making: Parent Advocates in New York City

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Estimation of genetic distances from human and mouse introns

Background
          Using genetic distances measured from exons, it has been observed that the mutation rate is not constant along mammalian chromosomes. Exons constitute only 1% of the human genome, however, and thus they cannot provide a complete picture of the mutational variation in the genome.
        
        
          Results
          I calculated genetic distances between 504 human introns and their orthologous mouse counterparts from a set of 63 pairs of human and mouse genes scattered through the genome using a recently developed method that can extract reliably aligned regions from the introns in an objective manner. I found a significant correlation between the genetic distance measured in the conserved intron segments and the synonymous and nonsynonymous distances measured in the corresponding coding exons, indicating that genes with fast-evolving exons tend to have fast-evolving introns, and vice versa.
        
        
          Conclusions
          These results indicate that introns, which extend over almost a quarter of the human genome, contain useful information for fully understanding the mutational dynamics of human and mouse genomes. This work also supports the idea that there is a mutational force that fluctuates nonrandomly along the genome, and shows for the first time that this force affects the introns and the synonymous and nonsynonymous positions in the exons of the genes simultaneously.
Cancer Mapping Data: 2011-2015

The Cancer Mapping data consists of counts of newly diagnosed cancer among New York State residents and is in response to legislation regarding "Cancer incidence and environmental facility maps" signed into law in 2010 (Public Health Law §2401-B). The law specifies the publication of maps showing cancer counts for small geographic areas along with certain facilities regulated by the State Department of Environmental Conservation. The official web site is called Environmental Facilities and Cancer Mapping.

The dataset is ONLY for the cancer-related data fields on the Environmental Facilities and Cancer Mapping web site. This dataset includes observed counts for 23 separate anatomical sites at the level of census block group. Block groups are small geographic areas typically averaging 1,000 to 1,500 people. To protect confidentiality, each area contains a minimum of 6 total cancers among males and 6 total cancers among females.

For more information, check out http://www.health.ny.gov/statistics/cancer/registry/about.htm .
Longitudinal Pathways to Resilience in Maltreated Children

The objectives of this study were as follows: (1) To investigate stability and change in the longitudinal course of adaptation and maladaptation in maltreated and nonmaltreated low-income youth.  (2) To differentiate subgroups of maltreated children who evidence divergence in their longitudinal developmental course, including resilient children as well as children who show continuity of negative adaptation.  (3) To examine child characteristics, maltreatment experiences, family features, and aspects of the social ecology as mediators and moderators of individual differences in the developmental pathways exhibited longitudinally by maltreated and nonmaltreated youth.  (4) To identify factors that may promote resilient adaptation in maltreated children. To address these critical concerns, this investigation built upon a prior one-year longitudinal study funded by NCCAN (Cicchetti, Manly, & Lynch, 1994).  Prospective follow-up assessments of 300 six- to twelve-year-old low income, maltreated and nonmaltreated children were targeted at years three and four beyond the initial baseline assessments.  A total of 300 school-aged children were included in the original study (Dataset #096).  Of these, 263 were obtained at year three and 249 at year four.  Data regarding children's adaptation and current symptomatology was collected in the context of a summer camp program that the children attended.  In addition, home visits were conducted concurrently with the third year child camp assessments, during which time the parent or primary caregiver of each child in the study was interviewed.  Finally, information regarding children's history of maltreatment was scored from updated DSS records according to our maltreatment classification system.

Investigators: Dante Cicchetti, Ph.D.

University of Rochester, Rochester, NY



Fred Rogosch, Ph.D.

Mount Hope Family Center, Rochester, NY



Jody Todd Manly, Ph.D.

University of Rochester, Rochester, NY



Michael Lynch, Ph.D.

University of Rochester, Rochester, NY
Compound 528698: 2-Cyclopenten-1-one, 3-ethyl-2-hydroxy-4-methyl-

Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-2-hydroxy-4-methylcyclopent-2-en-1-one. Molecular Formula: C8H12O2. Molecular Weight: 140.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526779: 8-Hydroxy-stearic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 8-[tert-butyl(dimethyl)silyl]oxyoctadecanoate. Molecular Formula: C25H52O3Si. Molecular Weight: 428.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Chlamydia trachomatis infection to Coccidioidomycosis

NNDSS - Table II. Chlamydia trachomatis infection to Coccidioidomycosis - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.
MD COVID-19 Total Doses Distributed Statewide

<b>WARNING:</b> This asset has been deprecated and will no longer be updated (last updated 4/29/2022). This was formerly a weekly update.

<b>Summary</b>
The cumulative number of COVID-19 vaccines distributed in Maryland.

<b>Description</b>
The MD COVID-19 - Total Doses Distributed Statewide data layer is a collection of the statewide COVID-19 vaccines that have been reported into VTrckS. Doses distributed also account for doses of vaccine provided to the District of Columbia to vaccinate Maryland residents who work in DC.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. 

The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
2011-2012 NSDUH: Other Sources of State-level Data

A variety of surveys and data systems other than the National Survey on Drug Use and Health (NSDUH) collect data on substance use and mental health problems. It is useful to consider the results of these other studies when discussing NSDUH data. This document briefly describes one of these other data systems that publish State estimates and presents selected comparisons with NSDUH results. The State-level survey that collects data on substance use discussed in this document is the Behavioral Risk Factor Surveillance System (BRFSS), sponsored by the Centers for Disease Control and Prevention (CDC). Another CDC data system that provides State-level substance use estimates for most but not all States is the Youth Risk Behavior Survey (YRBS).
Patent AT-E401000-T1: [Translated] SMOKE POT

The smoke pot, containing a powder charge (4) and an igniter, consists of an outer support (2) for an inner container (1) that holds the charge and has an aperture in its base closed by a thermo-fusible seal (3). The inner container is in the shape of a truncated cone that tapers towards its base and is open at the top, and the heat to burn the powder charge is provided by a charcoal pellet (5) with a cavity in its upper face to receive the part of the container base with the seal, while a spring (7) and plastic film disc (9) hold the pellet against the base. A second thermo-fusible seal (20) covers the top of the container.
Compound 527525: 1-(prop-2-en-1-yl)-1H-pyrrole

Chemical compound data from PubChem database. IUPAC Name: 1-prop-2-enylpyrrole. Molecular Formula: C7H9N. Molecular Weight: 107.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial

Background
          The timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia (AML). We postulated that granulocyte colony-stimulating factor (G-CSF) might enhance the cytotoxicity of EMA by increasing the proportion of leukemic blasts in S-phase. We added G-CSF to EMA (EMA-G) for therapy of advanced high-risk AML patients.
        
        
          Methods
          High-risk AML was defined as refractory, relapsed or secondary to either an antecedent hematologic disorder or exposure to cytotoxic agents. The patients were treated with one course of EMA-G consisting of mitoxantrone and cytarabine on days 1–3, and etoposide and cytarabine on days 8–10. G-CSF was started on day 4 and continued until absolute neutrophil count recovered.
        
        
          Results
          Thirty patients were enrolled. The median age was 51 years (range, 25–75). Seventeen (61%) patients had unfavorable cytogenetic karyotypes. Twenty (69%) patients had secondary AML. Ten (34%) had relapsed disease. Four (14%) had refractory AML. Three (10%) patients died from febrile neutropenia and sepsis. Major non-hematologic toxicity included hyperbilirubimenia, renal insufficiency, mucositis, diarrhea, nausea and vomiting, skin rash. A complete remission was achieved in 13 (46%) patients. Median overall survival was 9 months (range, 0.5–66). Median relapse-free survival (RFS) for those who had a CR was 3 months (range, 0.5–63) with RFS censored at the time of allogeneic bone marrow transplantation or peripheral stem cell transplantation for 6 of the patients.
        
        
          Conclusions
          EMA-G is a safe and efficacious option for induction chemotherapy in advanced, high-risk AML patients. The activity of EMA may be increased if applied in patients with less advanced disease.